NASDAQ
UTHR
Last Price
US $526.66
KEY FIGURES
MKT CAP
$22.4B
EPS
TTM
$29.60
PEG
TTM
2.35x
P/E
TTM
17.80x
P/S
TTM
7.23x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
19.24%
Return on equity
ROIC: 18.81%
Valuation History
18.7X
Price to Earnings
EV/EBITDA: 12.9X
Cash flow
Profit margin
16.50%
(FY vs FY)
EBITDA Y/Y
22.99%
(FY vs FY)
Cash flow Y/Y
8.37%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $526.66
-18.35%
Default assumptions
EBITDA Multiple
Fair Value
Market $526.66
-38.09%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
United Therapeutics Corporation cash flow to debt ratio of 4.15K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial risk - Healthy cash flow growth.
United Therapeutics Corporation's free cash flow has decreased -3.69% from $1.08G last year to $1.04G, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
United Therapeutics Corporation's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
United Therapeutics Corporation's debt has decreased relative to shareholder equity from 0.05 last year to 0.00 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
United Therapeutics Corporation has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
United Therapeutics Corporation earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
United Therapeutics Corporation's profit margin has decreased (-2.21%) in the last year from 41.53% to 40.61%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
United Therapeutics Corporation's short-term assets of $3.70G exceed its short-term liabilities of $560.60M
Increasing performance - ROA.
United Therapeutics Corporation's return on assets of 19.17% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
United Therapeutics Corporation's return on equity of 19.24%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
United Therapeutics Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
United Therapeutics Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
United Therapeutics Corporation has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
United Therapeutics Corporation has a free cash flow yield of 4.66%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
United Therapeutics Corporation's yearly earnings has increased 11.68% since last year from $1.20G to $1.33G, signaling increasing performance
Increasing performance - Healthy revenue growth.
United Therapeutics Corporation's yearly revenue has increased 10.61% since last year from $2.88G to $3.18G, signaling increasing performance
Increasing performance - ROIC.
ROIC 18.81% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
United Therapeutics Corporation's 3-year revenue CAGR of 18.02% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
United Therapeutics Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
United Therapeutics Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
United Therapeutics Corporation is overvalued relative to its fair value price of 430.00 based on Discounted Cash Flow model
Undervalued - Earnings yield.
United Therapeutics Corporation has an earnings yield of 5.62%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
United Therapeutics Corporation is overvalued relative to its fair value price of 326.06 based on EBITDA multiple model
Undervalued - EV/EBITDA.
United Therapeutics Corporation has an EV/EBITDA ratio of 11.45x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
United Therapeutics Corporation has a PEG-ratio over 1 which is considered overvalued
Undervalued - P/B ratio.
United Therapeutics Corporation has a price-to-book ratio of 3.88x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
United Therapeutics Corporation has a price-to-sales ratio of 7.23x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue